My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 333

    1.

    Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.

    Larsen PJ, Jensen PB, Sørensen RV, Larsen LK, Vrang N, Wulff EM, Wassermann K.

    Diabetes. 2003 Sep;52(9):2249-59.PMID: 12941763 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.

    Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU.

    Diabetes. 2003 Sep;52(9):2331-7.PMID: 12941773 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.

    Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye JM, Sauerberg P, Wassermann K.

    Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E841-54. Epub 2002 Dec 10.PMID: 12475752 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.

    Pickavance LC, Brand CL, Wassermann K, Wilding JP.

    Br J Pharmacol. 2005 Feb;144(3):308-16.PMID: 15655531 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.

    Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T.

    Diabetes. 1998 Dec;47(12):1841-7.PMID: 9836514 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    A peroxisome proliferator-activated receptor gamma agonist influenced daily profile of energy expenditure in genetically obese diabetic rats.

    Yoshida Y, Ichikawa M, Ohta M, Kanai S, Kobayash M, Ichimaru Y, Shimazoe T, Watanabe S, Funakoshi A, Miyasak K.

    Jpn J Pharmacol. 2002 Mar;88(3):279-84.PMID: 11949882 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.

    Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M.

    Endocrinology. 2006 Sep;147(9):4517-24. Epub 2006 Jun 1.PMID: 16740970 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.

    Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK.

    Biochem Biophys Res Commun. 2002 Aug 16;296(2):293-9.PMID: 12163016 [PubMed - indexed for MEDLINE]Related articles

    9.

    Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation.

    Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW.

    Diabetes. 2001 Feb;50(2):411-7.PMID: 11272155 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.

    Ye JM, Iglesias MA, Watson DG, Ellis B, Wood L, Jensen PB, Sørensen RV, Larsen PJ, Cooney GJ, Wassermann K, Kraegen EW.

    Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E531-40.PMID: 12556350 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.

    Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM.

    Biochem Biophys Res Commun. 2005 Oct 28;336(3):747-53.PMID: 16157299 [PubMed - indexed for MEDLINE]Related articles

    12.

    Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.

    Fernandes-Santos C, Carneiro RE, de Souza Mendonca L, Aguila MB, Mandarim-de-Lacerda CA.

    Nutrition. 2009 Jul-Aug;25(7-8):818-27. Epub 2009 Mar 5.PMID: 19268533 [PubMed - indexed for MEDLINE]Related articles

    13.

    Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.

    Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, Feingold KR.

    Endocrinology. 2000 Nov;141(11):4021-31.PMID: 11089532 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.

    Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS.

    Diabetes Metab Res Rev. 2003 Nov-Dec;19(6):487-93.PMID: 14648808 [PubMed - indexed for MEDLINE]Related articles

    15.

    Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.

    Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW.

    Endocrinology. 2006 Sep;147(9):4252-62. Epub 2006 May 25.PMID: 16728496 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.

    Desouza CV, Murthy SN, Diez J, Dunne B, Matta AS, Fonseca VA, McNamara DB.

    J Cardiovasc Pharmacol Ther. 2003 Dec;8(4):297-305.PMID: 14740079 [PubMed - indexed for MEDLINE]Related articles

    17.

    A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.

    Fukui Y, Masui S, Osada S, Umesono K, Motojima K.

    Diabetes. 2000 May;49(5):759-67.PMID: 10905484 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.

    Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R.

    Br J Pharmacol. 2003 Oct;140(3):527-37. Epub 2003 Sep 1.PMID: 12970088 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.

    Liang F, Wang F, Zhang S, Gardner DG.

    Endocrinology. 2003 Sep;144(9):4187-94.PMID: 12933694 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of fenofibrate on lipid metabolism in adipose tissue of rats.

    Ferreira AV, Parreira GG, Green A, Botion LM.

    Metabolism. 2006 Jun;55(6):731-5.PMID: 16713430 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity